Abstract: Monoclonal antibodies to transforming growth factor beta (TGF-B) are prepared from hybrid cell lines by immunizing with TGF-B2. The antibodies may be of any isotype and may be of any mammalian origin such as murine or human origin. Therapeutic applications utilizing the TGF-B monoclonal antibody are also disclosed.
Type:
Grant
Filed:
March 21, 2000
Date of Patent:
July 16, 2002
Assignee:
Genzyme Corporation
Inventors:
James R. Dasch, Doran R. Pace, III, Wendy O. Waegell
Abstract: Cytotoxic T lymphocyte responses are effectively induced to an antigen of interest, particularly viral, bacterial, parasitic and tumor antigens. Compositions, including pharmaceutical compositions, of CTL-inducing peptide and an adjuvant or a lipidated peptide which induces a helper T cell (HTL) response stimulate the antigen specific CTL response. Among the viral antigens to which the CTL responses are effectively induced in humans are those of hepatitis B. The CTL response may be optimized by a regimen of two or more booster administrations. Cocktails of two or more CTL inducing peptides are employed to optimize epitope and/or MHC class I restricted coverage.
Type:
Grant
Filed:
February 16, 1994
Date of Patent:
July 16, 2002
Assignee:
Epimmune Inc.
Inventors:
Maria A. Vitiello, Robert W. Chestnut, Alessandro D. Sette, Esteban Celis, Howard Grey
Abstract: The claimed invention provides methods of detecting and typing HCV using nucleic acid molecules encoding type specific and type-cluster specific epitopes. The nucleic acid molecules flanking regions encoding type specific or type cluster specific epitopes are useful in priming the polymerase chain reaction to determine the genotype an HCV isolate.
Abstract: A method for boosting an immune response against meningococcal capsular antigen is disclosed. The method entails administering a first glycoconjugate vaccine composition to a subject to provide an initial state of anti-meningococcal immunity, and then boosting the anti-meningococcal immunity by administration of a second, boosting vaccination. Also disclosed is the use of vaccine compositions in the preparation of anti-meningococcal medicaments. The use entails administering a first glycoconjugate vaccine composition to a subject to provide an initial state of anti-meningococcal immunity, and then boosting the anti-meningococcal immunity by administration of a second, boosting vaccination.
Abstract: Mammalian deep orange tumor suppressor genes are disclosed. Mammalian deep orange genes and proteins can be used as therapeutics, as diagnostic tools, and in making animal models. The genes can be used to identify a q13 region of a human chromosome 15 and a central region of a mouse chromosome 2.
Abstract: A novel method using anti-interleukin 2 receptor monoclonal antibodies for treating patients having severe viral hepatitis C is described. The inventive method may be used to treat recurrent hepatitis C following liver transplantation, thereby reducing complications in recipients of liver allografts.
Type:
Grant
Filed:
October 29, 1999
Date of Patent:
June 18, 2002
Assignee:
University of Miami
Inventors:
Antonio Pinna, Camillo Ricordi, Andreas G. Tzakis
Abstract: This invention provides the TSC403 gene having a nucleotide sequence coding for the amino acid sequence of SEQ ID NO:1, which is a novel gene of great utility particularly in the field of research, diagnosis, therapy, etc. for cancer of the lung, among other diseases.
In addition, this invention provides the human ING1L gene comprising a nucleotide sequence coding for the amino acid sequence of SEQ ID NO:4, which is a novel human gene useful for regulating the cell cycle, inhibiting or activating cell proliferation, studies on metabolic aging or apoptosis of cells, pathological exploration, diagnosis and therapy of cancer and other diseases, and screening for the development of new drugs.
Abstract: A method of augmenting T cell-mediated immunity against Toxoplasma gondii is provided. Immunization with Toxoplasma gondii soluble parasite antigen and exogenous rIL-15 was found to protect against Toxoplasma gondii infection.
Abstract: The present invention relates to a TCF mutant having a novel amino acid sequence which is obtained by mutagenesis of one or more amino acid between N-terminus and the first kringle of the amino acid sequence of native TCF and has lowered affinity to heparin and/or elevated biological activity. The present TCF mutant is prepared by gene manipulation of TCF. The TCF mutants of the present invention have proliferative activity and/or growth stimulative activity in hepatocyte and beneficial as a therapeutic agent for various hepatic diseases and an antitumor agent.
Abstract: This invention provides a non-naturally occurring targeted lipolytic compound comprising a lipolytic agent linked to a targeting agent. In an embodiment, the lipolytic agent is covalently attached to the targeting agent. In an embodiment, the lipolytic agent is a phospholipase and the targeting agent is a viral receptor. This invention further provides for therapeutic uses of the non-naturally occurring targeted lipolytic compound. In an embodiment, the non-naturally occurring targeted lipolytic compound neutralizes virions of the human immunodeficiency virus (HIV).
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
June 4, 2002
Assignee:
The Trustees of Columbia University in the City of New
York
Abstract: The present invention provides a hybrid virus comprising poliovirus and the hepatitis C virus protease NS3 and a target site for NS3. The hybrid virus is useful for screening for drugs against hepatitis C virus.
Abstract: The invention relates to the removal of viruses from aqueous solutions, as a rule protein solutions, by ultrafiltration. This entails the viruses to be removed being increased in size by incubation with a high molecular weight receptor binding thereto, preferably a specific antibody, so that, on the one hand, the separation effect is improved and, on the other hand, a larger pore diameter which can now be chosen for the filters used also makes it possible for smaller viruses to be separated from larger protein molecules present in protein solutions, and, where appropriate, the filtration rate is increased.
Type:
Grant
Filed:
February 7, 1996
Date of Patent:
May 21, 2002
Assignee:
Aventis Behring GmbH
Inventors:
Dieter Bernhardt, Albrecht Gröner, Thomas Nowak
Abstract: The present invention is directed to assays for detecting antibodies in a sample in a single incubation step. The assays employ universal solid phases and/or universal detectable markers, and facilitate the detection and differentiation of antigens from the same source or from different sources in a single test sample. The present invention includes test kits for performing the methods according to the invention.
Type:
Grant
Filed:
September 22, 1998
Date of Patent:
May 21, 2002
Assignee:
Chiron Corporation
Inventors:
David Y. Chien, Phillip Arcangel, Stephen Tirell, Wanda Zeigler
Abstract: Isolated nucleic acid molecules are disclosed, comprising an alphavirus nonstructural protein gene which, when operably incorporated into a recombinant alphavirus particle, eukaryotic layered vector initiation system, or RNA vector replicon, has a reduced level of vector-specific RNA synthesis, as compared to wild-type, and the same or greater level of proteins encoded by RNA transcribed from the viral junction region promoter, as is compared to a wild-type recombinant alphavirus particle. Also disclosed are RNA vector replicons, alphavirus vector constructs, and eukaryotic layered vector initiation systems which contain the above-identified nucleic acid molecules.
Type:
Grant
Filed:
October 8, 1999
Date of Patent:
May 21, 2002
Assignees:
Chiron Corporation, Washington University
Inventors:
Thomas W. Dubensky, Jr., John M. Polo, Barbara A. Belli, Sondra Schlesinger, Sergey A. Dryga, Ilya Frolov
Abstract: Production of enveloped RNA virus-like particles intracellularly in vitro in insect cells using a recombinant baculovirus vector containing a cDNA coding for viral structural proteins is disclosed. In vitro production and purification of hepatitis C virus (HCV)-like particles containing HCV core protein, E1 protein and E2 protein is disclosed. Production of antibodies in vivo to the purified HCV-like particles is disclosed.
Type:
Grant
Filed:
April 21, 1999
Date of Patent:
May 14, 2002
Assignee:
The United States of America as represented by the Department
of Health & Human Services
Abstract: Synthetic polypeptides having at least one antigenic site of a prion protein, methods for their use and manufacture, antibodies raised against such polypeptides and diagnostic kits containing these polypeptides or antibodies.
Type:
Grant
Filed:
May 13, 1998
Date of Patent:
April 30, 2002
Assignee:
Proteus Molecular Design Limited
Inventors:
Robert Vincent Fishleigh, Barry Robson, Roger Paul Mee
Abstract: The present invention provides a purified preparation containing, for example, at least one polypeptide selected from the group consisting of proteins encoded by one or more open reading frames (ORF's) of an Iowa strain of porcine reproductive and respiratory syndrome virus (PRRSV), antigenic regions of such proteins which are at least 5 amino acids in length and which effectively protect a porcine host against a subsequent challenge with a PRRSV isolate, and combinations thereof in which amino acids non-essential for antigenicity may be conservatively substituted. The present invention also concerns a vaccine comprising an effective amount of such a protein; antibodies which specifically bind to such a protein; methods of producing the same; and methods of protecting a pig against a PRRSV, treating a pig infected by a PRRSV, and detecting PRRSV in a pig.
Type:
Grant
Filed:
February 6, 1998
Date of Patent:
April 30, 2002
Assignee:
Iowa State University Research Foundation
Abstract: The present invention provides a novel method for the identification and clonal isolation of antibodies that bind to unique epitopes. The method is based on the use of antibodies as solid phase capture reagents to bind a known capture antibody epitope, thereby precluding the capture antibody epitope from being presented to a population of antibodies to be screened. The method is particularly suited for screening libraries of cloned antibodies, such as phage display combinatorial antibodies. An antibody specific for herpes simplex virus (HSV), was employed as a model for the assay.
Type:
Grant
Filed:
November 18, 1997
Date of Patent:
April 23, 2002
Assignee:
The Scripps Research Institute
Inventors:
Dennis R. Burton, Roberto Burioni, R. Anthony Williamson, Pietro P. Sanna